NCT05328440: First-line Treatment of Dalpiciclib Combined With Pyrotinib for HER2+ Advanced Breast Cancer(DAP-Her-02)

Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Therapeutic Antibody, Tyrosine-Kinase Inhibitor, Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have at least one measurable lesion or bone-only metastasis
Exclusions: Patients with symptomatic brain metastasis; Patients with previous systemic treatment for advanced disease; Patients with prior exposure to tyrosine kinase inhibitors targeting HER2 (Nerlynx/neratinib, Tykerb/lapatinib, Tukysa/tucatinib, pyrotinib, etc.); Patients previously treated with any CDK4 / 6 inhibitor (e.g. Ibrance/palbociclib, Verzenio/abemaciclib, Kisqali/ribociclib)

Comments are closed.

Up ↑